Q
QuantAbundanceAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

30,455 signal articles · 146 in last 24h · 154,143 total before filter · latest 1h ago
146last 24h
875last 7d
147● bullish (7d)
96● bearish (7d)
214publishers
AllMacro211Earnings108M&A125Regulatory21Product21Analyst17
✕ clear all filtersticker: NOVTSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Is Novanta (NOVT) A Bargain Following Strong Growth And Demand Outlook?
Simply Wall St.5d agoneutral
Is Novanta (NOVT) A Bargain Following Strong Growth And Demand Outlook?

Recent commentary on Novanta (NOVT) has focused on its revenue growth profile and projected demand pickup, with solid gross margins drawing new attention to how the stock’s recent returns compare with those fundamentals. Short term trading pressure has been clear, with the share price down 9.2% over the past week and 14.3% over 90 days. Yet Novanta’s year to date share price return of 19.8% and 1 year total shareholder return of 16.1% point to momentum that has cooled rather than...

Is Novanta’s (NOVT) High-Margin Revenue Momentum Redefining Its Competitive Moat?
Simply Wall St.5d agoneutral
Is Novanta’s (NOVT) High-Margin Revenue Momentum Redefining Its Competitive Moat?

In recent commentary, Novanta (NASDAQ:NOVT) has been highlighted for its multi-year annual revenue growth of 10.7% and a gross margin of 44.4%, reflecting perceived market share gains and strong product positioning. This attention centers on Novanta’s combination of demand acceleration expectations and high-margin products, which analysts view as evidence of superior competitive capabilities. Next, we will examine how this focus on Novanta’s revenue momentum and margins may influence the...

1 High-Flying Stock Worth Your Attention and 2 We Ignore
StockStory6d agoneutral
1 High-Flying Stock Worth Your Attention and 2 We Ignore

“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.

Novanta’s (NOVT) Second Quarter Shows Profits Outrunning Sales
Insider Monkey20d agoneutral
Novanta’s (NOVT) Second Quarter Shows Profits Outrunning Sales

On August 5, Novanta Inc. (NASDAQ:NOVT) reported second quarter results showing something rarer than strong revenue growth: profit growth that beat it by a wide margin. Revenue rose 10.3% year over year to $265.8 million, but net income nearly tripled and cash from operations quadrupled. That kind of gap between the top and bottom line […]

1 Small-Cap Stock with Promising Prospects and 2 We Brush Off
StockStory38d agoneutral
1 Small-Cap Stock with Promising Prospects and 2 We Brush Off

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

5 Revealing Analyst Questions From Novanta’s Q2 Earnings Call
StockStory41d agoneutral
5 Revealing Analyst Questions From Novanta’s Q2 Earnings Call

Novanta's second quarter was marked by broad-based organic growth across all business units and a favorable response from the market. Management attributed the strong results to both an acceleration in new product revenue—up more than 50% year-over-year—and operational improvements, including factory consolidations. CEO Matthijs Glastra highlighted that all business units grew organically and pointed to increased customer demand in precision robotics, AI-driven manufacturing, and minimally invas

NOVT Q2 Deep Dive: Acquisition and Manufacturing Moves Drive Outlook Higher
StockStory45d agoneutral
NOVT Q2 Deep Dive: Acquisition and Manufacturing Moves Drive Outlook Higher

Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.3% year on year to $265.8 million. On top of that, next quarter’s revenue guidance ($302 million at the midpoint) was surprisingly good and 14.9% above what analysts were expecting. Its non-GAAP profit of $0.89 per share was 7.2% above analysts’ consensus estimates.

Novanta (NOVT) Lifted Guidance And Closed Riverpoint, Is The Upside Already Priced In?
Simply Wall St.46d agoneutral
Novanta (NOVT) Lifted Guidance And Closed Riverpoint, Is The Upside Already Priced In?

What Novanta’s latest guidance and Q2 results mean for the stock Novanta (NOVT) put fresh numbers on the table on 5 August 2026, pairing new third quarter and full year revenue guidance with second quarter results and the recently closed Riverpoint Medical acquisition. The company now guides third quarter 2026 GAAP revenue to US$300 million to US$304 million, with the range reflecting an expected contribution from Riverpoint Medical and an assumption of steady foreign exchange rates. For full...

Novanta (NOVT) Closes Its Largest Acquisition】【。
Simply Wall St.46d agoneutral
Novanta (NOVT) Closes Its Largest Acquisition】【。

Novanta (NasdaqGS:NOVT) has closed its acquisition of RiverPoint Medical, the largest deal in the company's history. The transaction expands Novanta's exposure to medical end markets and is expected to be immediately accretive to revenue growth and margins. Management is accelerating a manufacturing restructuring plan alongside the RiverPoint integration, with potential long-term effects on efficiency and profitability. For investors watching how medical technology companies scale up and...

Novanta Q2 Earnings Call Highlights
MarketBeat48d agoneutral
Novanta Q2 Earnings Call Highlights

Novanta (NASDAQ:NOVT) reported second-quarter results marked by 9% organic sales growth, expanding margins and higher operating cash flow, while raising its full-year outlook following the late-July closing of its Riverpoint Medical acquisition. Chair and Chief Executive Officer Matthijs Glastra sa

Increased Bookings Reinforce Novanta’s (NOVT) Broadening Organic Momentum
Insider Monkey49d agoneutral
Increased Bookings Reinforce Novanta’s (NOVT) Broadening Organic Momentum

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI enthusiasm […]

Novanta’s (NASDAQ:NOVT) Q2 CY2026 Sales Top Estimates, Guides for Strong Full-Year Sales
StockStory50d agoneutral
Novanta’s (NASDAQ:NOVT) Q2 CY2026 Sales Top Estimates, Guides for Strong Full-Year Sales

Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) announced better-than-expected revenue in Q2 CY2026, with sales up 10.3% year on year to $265.8 million. On top of that, next quarter’s revenue guidance ($302 million at the midpoint) was surprisingly good and 14.9% above what analysts were expecting. Its non-GAAP profit of $0.89 per share was 7.2% above analysts’ consensus estimates.

3 Russell 2000 Stocks We Find Risky
StockStory70d agobearish
3 Russell 2000 Stocks We Find Risky

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.

2 High-Flying Stocks Worth Investigating and 1 We Avoid
StockStory84d agoneutral
2 High-Flying Stocks Worth Investigating and 1 We Avoid

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.

The Bull Case For Novanta (NOVT) Could Change Following An Earnings-Driven Analyst Upgrade - Learn Why
Simply Wall St.89d agobullish
The Bull Case For Novanta (NOVT) Could Change Following An Earnings-Driven Analyst Upgrade - Learn Why

Novanta was recently upgraded to a Zacks Rank #2 (Buy), reflecting increased analyst optimism tied to an upward revision in earnings estimates. This earnings-driven upgrade highlights how changing expectations about Novanta's profit outlook can influence investor attention and perceived business strength over time. Next, we'll examine how the upgraded earnings outlook and analyst ranking could reshape Novanta's existing investment narrative and risk profile. Invest in the nuclear...

Broader Market Settles Lower as Chip Stocks Sink
Barchart107d agoneutral
Broader Market Settles Lower as Chip Stocks Sink

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.26%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.17%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.12%. June E-mini S&P futures (ESM26 ) fell -0.36%, and June E-mini Nasdaq futures...